Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem-vaborbactam in carbapenem-resistant Enterobacteriaceae infections (Phase III, China)
CTR20243394Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem + vaborbactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI), carbapenem-resistant Enterobacterales bacteremia, sponsored by Qilu Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
meropenem + vaborbactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)complicated intra-abdominal infection (cIAI)carbapenem-resistant Enterobacterales bacteremia
Beyond the preview
Go deeper on CTR20243394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243394.